Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Equillium, Inc. - Common Stock (NQ:EQ)

1.410 +0.080 (+6.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Equillium, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Equillium Announces $7.5 Million Share Repurchase Program
From Equillium, Inc.
Via Business Wire
Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences
From Equillium, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
From Equillium, Inc.
Via Business Wire
Autoimmune Biotech Scores $26M Payment, Up To $139M To Advance Phase 3 Research
 
Via Benzinga
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
From Equillium, Inc.
Via Business Wire
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation
From Equillium, Inc.
Via Business Wire
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates
From Equillium, Inc.
Via Business Wire
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference
From Equillium, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR
From Equillium, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Alphabet To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Wednesday
Loop Capital boosted the price target for Alphabet Inc. (NASDAQ: GOOGL) from $120 to $125. Loop Capital analyst Rob Sanderson maintained a Buy rating. Alphabet shares fell 3.7% to $103.70 in pre-market... 
Via Benzinga
Equillium to Present at the SVB Securities Annual Global Healthcare Conference
From Equillium, Inc.
Via Business Wire
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
From Equillium, Inc.
Via Business Wire
Metacrine, Equillium And 3 Stocks To Watch Heading Into Tuesday
With US stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
From Equillium, Inc.
Via Business Wire
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
From Equillium, Inc.
Via Business Wire
Why iBio Shares Are Trading Lower By Around 48%; Here Are 23 Stocks Moving Premarket
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 71.3% to $0.7190 in pre-market trading after the company reported withdrawal of registration statement. 
Via Benzinga
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
From Equillium, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  On Friday, 72 companies hit new 52-week lows. 
Via Benzinga
How Equillium Inc Could Help Lead The Fight Against Autoimmune Diseases
Equillium Inc. (NASDAQ: EQ) is a clinical-stage biotechnology company that focuses on immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders. 
Via Benzinga
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates
From Equillium, Inc.
Via Business Wire
Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022
From Equillium, Inc.
Via Business Wire
Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata
From Equillium, Inc.
Via Business Wire
Equillium to Present at Two Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit
From Equillium, Inc.
Via Business Wire
Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease
From Equillium, Inc.
Via Business Wire
Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference
From Equillium, Inc.
Via Business Wire
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.